New insights into molecules and pathways of cancer metabolism and therapeutic implications

Tang, Zhenye; Xu, Zhenhua; Zhu, Xiao; Zhang, Jinfang

doi:10.1002/cac2.12112

Cited by 80 publications

(51 citation statements)

References 149 publications

(204 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although current chemotherapy can prolong the survival time of tumor patients (60,61), the prognosis and economic burden are still difficult problems in clinical work. Therefore, it is urgent to explore the pathogenesis and new therapeutic methods of hematologic malignancy, such as targeted therapy (62)(63)(64).…”

Section: Discussionmentioning

confidence: 99%

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

et al. 2021

Self Cite

View full text Add to dashboard Cite

N6-methyladenosine (m6A) is one of the most active modification factors of mRNA, which is closely related to cell proliferation, differentiation, and tumor development. Here, we explored the relationship between the pathogenesis of hematological malignancies and the clinicopathologic parameters. The datasets of hematological malignancies and controls were obtained from the TCGA [AML (n = 200), DLBCL (n = 48)] and GTEx [whole blood (n = 337), blood vascular artery (n = 606)]. We analyzed the m6A factor expression differences in normal tissue and tumor tissue and their correlations, clustered the express obvious clinical tumor subtypes, determined the tumor risk score, established Cox regression model, performed univariate and multivariate analysis on all datasets. We found that the AML patients with high expression of IGF2BP3, ALKBH5, and IGF2BP2 had poor survival, while the DLBCL patients with high expression of METTL14 had poor survival. In addition, “Total” datasets analysis revealed that IGF2BP1, ALKBH5, IGF2BP2, RBM15, METTL3, and ZNF217 were potential oncogenes for hematologic system tumors. Collectively, the expressions of some m6A regulators are closely related to the occurrence and development of hematologic system tumors, and the intervention of specific regulatory factors may lead to a breakthrough in the treatment in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cancer cells are characterized by metabolic transformation, migration and uncontrolled proliferation [ 43 ]. Bioenergetic changes in tumors include the acceleration of glycolysis, elevation of glutaminolytic flux, enhancement of mitochondrial biogenesis, stimulation of the PPP and biosynthesis of macromolecules [ 4 ].…”

Section: Structural and Functional Aspects Of Melatoninmentioning

confidence: 99%

Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects

Samec

Líšková

Koklesová

et al. 2021

Cancers

View full text Add to dashboard Cite

Metabolic reprogramming characterized by alterations in nutrient uptake and critical molecular pathways associated with cancer cell metabolism represents a fundamental process of malignant transformation. Melatonin (N-acetyl-5-methoxytryptamine) is a hormone secreted by the pineal gland. Melatonin primarily regulates circadian rhythms but also exerts anti-inflammatory, anti-depressant, antioxidant and anti-tumor activities. Concerning cancer metabolism, melatonin displays significant anticancer effects via the regulation of key components of aerobic glycolysis, gluconeogenesis, the pentose phosphate pathway (PPP) and lipid metabolism. Melatonin treatment affects glucose transporter (GLUT) expression, glucose-6-phosphate dehydrogenase (G6PDH) activity, lactate production and other metabolic contributors. Moreover, melatonin modulates critical players in cancer development, such as HIF-1 and p53. Taken together, melatonin has notable anti-cancer effects at malignancy initiation, progression and metastasing. Further investigations of melatonin impacts relevant for cancer metabolism are expected to create innovative approaches supportive for the effective prevention and targeted therapy of cancers.

show abstract

“…Although a series of features of this ligand are normal tissue, tumor cells are known to have the ability to inhibit tumor-specific t cell function. PD-L1 and CTLA-4 are the most studied checkpoint ligands (6,22).…”

Section: Immune Checkpoint Ligandsmentioning

confidence: 99%

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

Zhu

2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapy is a kind of therapy that can control and eliminate tumors by restarting and maintaining the tumor-immune cycle and restoring the body’s normal anti-tumor immune response. Although immunotherapy has great potential, it is currently only applicable to patients with certain types of tumors, such as melanoma, lung cancer, and cancer with high mutation load and microsatellite instability, and even in these types of tumors, immunotherapy is not effective for all patients. In order to enhance the effectiveness of tumor immunotherapy, this article reviews the research progress of tumor microenvironment immunotherapy, and studies the mechanism of stimulating and mobilizing immune system to enhance anti-tumor immunity. In this review, we focused on immunotherapy against tumor microenvironment (TME) and discussed the important research progress. TME is the environment for the survival and development of tumor cells, which is composed of cell components and non-cell components; immunotherapy for TME by stimulating or mobilizing the immune system of the body, enhancing the anti-tumor immunity. The checkpoint inhibitors can effectively block the inhibitory immunoregulation, indirectly strengthen the anti-tumor immune response and improve the effect of immunotherapy. We also found the checkpoint inhibitors have brought great changes to the treatment model of advanced tumors, but the clinical treatment results show great individual differences. Based on the close attention to the future development trend of immunotherapy, this study summarized the latest progress of immunotherapy and pointed out a new direction. To study the mechanism of stimulating and mobilizing the immune system to enhance anti-tumor immunity can provide new opportunities for cancer treatment, expand the clinical application scope and effective population of cancer immunotherapy, and improve the survival rate of cancer patients.

show abstract

New insights into molecules and pathways of cancer metabolism and therapeutic implications

Cited by 80 publications

References 149 publications

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases

Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects

The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity

Contact Info

Product

Resources

About